{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T19:12:57Z","timestamp":1791573177237,"version":"4.3.4"},"reference-count":53,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,5,14]],"date-time":"2022-05-14T00:00:00Z","timestamp":1652486400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,5,14]],"date-time":"2022-05-14T00:00:00Z","timestamp":1652486400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Endocr Disord"],"published-print":{"date-parts":[[2022,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Adrenocortical carcinoma (ACC) is a highly malignant urologic cancer and tends to metastasize. Although immune checkpoint inhibitors (ICIs) bring a glimmer of light to conquer ACC, only a fraction of patients have benefit from ICIs treatment. It is well known that tumor mutational burden (TMB) is closely associated with the efficacy and response rate of immunotherapy. However, its roles in ACC were not investigated.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>Using somatic mutations data of 92 ACC samples in TCGA database, we calculated their TMB values by the \u2018maftools\u2019 package in R software (Ver 3.6.3). To explore the roles of TMB in ICIs therapy, we have addressed this issue from three perspectives. First, the effects of TMB levels on tumor immune microenvironment (TIM) were analyzed through CIBERSORT algorithm, ssGSEA method and TIMER web server. Second, we investigated the expressive correlations between TMB level and five pivotal immune checkpoints based on Pearson coefficient. Third, the difference in TIDE score between high- and low-TMB groups was compared. The prognostic value of TMB was also evaluated. Besides, GSEA was performed to determine the changes in the activities of signaling pathways caused by TMB.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>TMB values in ACC samples were not high. The average of total mutation counts in each sample was only 21.5. High TMB could lead metabolic reprogramming and poor survival outcomes. However, it was unable to affect the infiltration levels of lymphocytes, and failed to facilitate the activities of immune-related pathways. Regarding immune checkpoints (ICs), only PD-L1 upregulation could result in a good prognosis, and TMB level did not correlate with the expressions of other ICs except for LAG3. There was no significant difference in TIDE score between high- and low-TMB groups. Combining the present results and previous study, we speculated that inadequate stimulation for neoantigens formation, intrinsic immune-resistance and special genomic alterations were three possible reasons for TMB limiting functions in TIM and ICIs. Besides, TMB was toughly applied in clinical practice due to its high cost of determination and non-universal definition of high TMB.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>TMB presents limiting effects on prediction for ICIs efficacy and prognostic assessment for ACC patients.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s12902-022-01017-3","type":"journal-article","created":{"date-parts":[[2022,5,14]],"date-time":"2022-05-14T08:03:04Z","timestamp":1652515384000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":14,"title":["Tumor mutational burden presents limiting effects on predicting the efficacy of\u00a0immune checkpoint inhibitors\u00a0and prognostic assessment\u00a0in adrenocortical carcinoma"],"prefix":"10.1186","volume":"22","author":[{"given":"Fangshi","family":"Xu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yibing","family":"Guan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peng","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li","family":"Xue","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yubo","family":"Ma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mei","family":"Gao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tie","family":"Chong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bin-Cheng","family":"Ren","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,5,14]]},"reference":[{"key":"1017_CR1","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1002\/cncr.24030","volume":"115","author":"M Fassnacht","year":"2009","unstructured":"Fassnacht M, Johanssen S, Quinkler M, Bucsky P, Hs Willenberg F, Beuschlein MT, et al. Limited prognostic value of the 2004 international union against cancer staging classification for adrenocortical carcinoma: proposal for a revised TNM classification. Cancer. 2009;115:243\u201350.","journal-title":"Cancer"},{"key":"1017_CR2","doi-asserted-by":"publisher","first-page":"5948","DOI":"10.1210\/jc.2019-00915","volume":"104","author":"J Tierney","year":"2019","unstructured":"Tierney J, Sv Chivukula J, Poirier SP, Schadde E, Hertl M, Kebebew E, et al. National Treatment Practice for adrenocortical carcinoma: have they changed and have we made any Progress? J Clin Endocrinol Metab. 2019;104:5948\u201356.","journal-title":"J Clin Endocrinol Metab"},{"key":"1017_CR3","doi-asserted-by":"publisher","first-page":"4812","DOI":"10.1210\/jc.2010-0990","volume":"95","author":"A Lacroix","year":"2010","unstructured":"Lacroix A. Approach to the patient with adrenocortical carcinoma. J Clin Endocrinol Metab. 2010;95:4812\u201322.","journal-title":"J Clin Endocrinol Metab"},{"key":"1017_CR4","doi-asserted-by":"publisher","first-page":"2189","DOI":"10.1056\/NEJMoa1200966","volume":"366","author":"M Fassnacht","year":"2012","unstructured":"Fassnacht M, Terzolo M, Allolio B, Baudin E, Haak H, Berruti A, et al. Combination chemotherapy in advanced adrenocortical carcinoma. N Engl J Med. 2012;366:2189\u201397.","journal-title":"N Engl J Med"},{"key":"1017_CR5","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1007\/s11934-018-0851-7","volume":"19","author":"A Tripathi","year":"2018","unstructured":"Tripathi A, Plimack ER. Immunotherapy for urothelial carcinoma: current evidence and future directions. Curr Urol Rep. 2018;19:109.","journal-title":"Curr Urol Rep"},{"key":"1017_CR6","doi-asserted-by":"crossref","unstructured":"Naing A, Meric-Bernstam F, Stephen B, Dd K, Hajjar J, Rodon Ahnert J, et al. Phase 2 study of pembrolizumab in patients with advanced rare cancers. J Immunother Cancer. 2020; 8(1): e000347.","DOI":"10.1136\/jitc-2019-000347"},{"issue":"40\u201350","key":"1017_CR7","first-page":"2020","volume":"131","author":"C Jd Fumet","year":"1990","unstructured":"Jd Fumet C, Truntzer MY, Ghiringhelli F. Tumour mutational burden as a biomarker for immunotherapy: current data and emerging concepts. Eur J Cancer (Oxford England). 1990;131(40\u201350):2020.","journal-title":"Eur J Cancer (Oxford England)"},{"key":"1017_CR8","doi-asserted-by":"publisher","first-page":"2093","DOI":"10.1056\/NEJMoa1801946","volume":"378","author":"MD Hellmann","year":"2018","unstructured":"Hellmann MD, Ciuleanu TE, Pluzanski A, Lee JS, Otterson GA, Audigier-Valette C, et al. Nivolumab plus Ipilimumab in lung cancer with a high tumor mutational burden. N Engl J Med. 2018;378:2093\u2013104.","journal-title":"N Engl J Med"},{"key":"1017_CR9","doi-asserted-by":"crossref","unstructured":"Valero C, Lee M, Hoen D, Zehir A, Mf B, Ve S, et al. Response rates to anti-PD-1 immunotherapy in microsatellite-stable solid tumors with 10 or more mutations per Megabase. JAMA Oncol. 2021;7(5):739\u201343.","DOI":"10.1001\/jamaoncol.2020.7684"},{"key":"1017_CR10","doi-asserted-by":"publisher","first-page":"1747","DOI":"10.1101\/gr.239244.118","volume":"28","author":"A Mayakonda","year":"2018","unstructured":"Mayakonda A, Lin D, Assenov Y, Plass C, Koeffler H. Maftools: efficient and comprehensive analysis of somatic variants in cancer. Genome Res. 2018;28:1747\u201356.","journal-title":"Genome Res"},{"key":"1017_CR11","doi-asserted-by":"crossref","unstructured":"Chan TA, Yarchoan M, Jaffee E, et al. Development of tumor mutation burden as an immunotherapy biomarker: utility for the oncology clinic. Ann Oncol. 2019;30(1):44\u201356.","DOI":"10.1093\/annonc\/mdy495"},{"key":"1017_CR12","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1186\/s13073-017-0424-2","volume":"9","author":"Z Chalmers","year":"2017","unstructured":"Chalmers Z, Cf Connelly D, Fabrizio LG, Sm Ali R, Ennis AS, et al. Analysis of 100,000 human cancer genomes reveals the landscape of tumor mutational burden. Genome Med. 2017;9:34.","journal-title":"Genome Med"},{"key":"1017_CR13","doi-asserted-by":"publisher","first-page":"577","DOI":"10.1177\/0962280209351925","volume":"18","author":"MC Wu","year":"2009","unstructured":"Wu MC, Lin X. Prior biological knowledge-based approaches for the analysis of genome-wide expression profiles using gene sets and pathways. Stat Methods Med Res. 2009;18:577\u201393.","journal-title":"Stat Methods Med Res"},{"key":"1017_CR14","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1007\/978-1-4939-7493-1_12","volume":"1711","author":"B Chen","year":"2018","unstructured":"Chen B, Khodadoust M, Liu CL, Newman A, Alizadeh A. Profiling tumor infiltrating immune cells with CIBERSORT. Methods Mol Biol (Clifton, NJ). 2018;1711:243\u201359.","journal-title":"Methods Mol Biol (Clifton, NJ)"},{"key":"1017_CR15","doi-asserted-by":"publisher","first-page":"453","DOI":"10.1038\/nmeth.3337","volume":"12","author":"A Newman","year":"2015","unstructured":"Newman A, Liu C, Green M, Gentles A, Feng W, Xu Y, et al. Robust enumeration of cell subsets from tissue expression profiles. Nat Methods. 2015;12:453\u20137.","journal-title":"Nat Methods"},{"key":"1017_CR16","doi-asserted-by":"publisher","first-page":"e108","DOI":"10.1158\/0008-5472.CAN-17-0307","volume":"77","author":"L Taiwen","year":"2017","unstructured":"Taiwen L, Jingyu F, Wang B, Nicole T, Qianming C, Liu Jun S, et al. TIMER: a web server for comprehensive analysis of tumor-infiltrating immune cells. Cancer Res. 2017;77:e108\u201310.","journal-title":"Cancer Res"},{"key":"1017_CR17","doi-asserted-by":"publisher","first-page":"1550","DOI":"10.1038\/s41591-018-0136-1","volume":"24","author":"P Jiang","year":"2018","unstructured":"Jiang P, Gu S, Pan D, Fu J, Sahu A, Hu X, et al. Signatures of T cell dysfunction and exclusion predict cancer immunotherapy response. Nat Med. 2018;24:1550\u20138.","journal-title":"Nat Med"},{"key":"1017_CR18","doi-asserted-by":"publisher","first-page":"5584","DOI":"10.1038\/s41467-020-19406-4","volume":"11","author":"L Nguyen","year":"2020","unstructured":"Nguyen L, Martens JWM, Van Hoeck A, Cuppen E. Pan-cancer landscape of homologous recombination deficiency. Nat Commun. 2020;11:5584.","journal-title":"Nat Commun"},{"key":"1017_CR19","doi-asserted-by":"publisher","first-page":"154","DOI":"10.3390\/cancers10060154","volume":"10","author":"M Kanapathipillai","year":"2018","unstructured":"Kanapathipillai M. Treating p53 mutant aggregation-associated cancer. Cancers (Basel). 2018;10:154.","journal-title":"Cancers (Basel)"},{"key":"1017_CR20","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1002\/ijc.11643","volume":"109","author":"HS Han","year":"2004","unstructured":"Han HS, Kwon YJ, Park SH, Kim EJ, Rho YS, Sin HS, et al. Potent effect of 5-HPBR, a butanoate derivative of 4-HPR, on cell growth and apoptosis in cancer cells. Int J Cancer. 2004;109:58\u201364.","journal-title":"Int J Cancer"},{"key":"1017_CR21","doi-asserted-by":"publisher","first-page":"269","DOI":"10.3390\/metabo9110269","volume":"9","author":"CL Silva","year":"2019","unstructured":"Silva CL, Olival A, Perestrelo R, Silva P, Tom\u00e1s H, C\u00e2mara JS. Untargeted urinary (1) H NMR-based Metabolomic pattern as a potential platform in breast cancer detection. Metabolites. 2019;9:269.","journal-title":"Metabolites"},{"key":"1017_CR22","doi-asserted-by":"publisher","first-page":"484","DOI":"10.1038\/d41586-018-05573-4","volume":"559","author":"C Frezza","year":"2018","unstructured":"Frezza C. Histidine metabolism boosts cancer therapy. Nature. 2018;559:484\u20135.","journal-title":"Nature"},{"key":"1017_CR23","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1016\/bs.apha.2015.04.003","volume":"74","author":"T Li","year":"2015","unstructured":"Li T, Apte U. Bile acid metabolism and signaling in cholestasis, inflammation, and cancer. Adv Pharmacol. 2015;74:263\u2013302.","journal-title":"Adv Pharmacol"},{"key":"1017_CR24","doi-asserted-by":"publisher","first-page":"516","DOI":"10.1093\/jnci\/djz166","volume":"112","author":"T K\u00fchn","year":"2020","unstructured":"K\u00fchn T, Stepien M, L\u00f3pez-Nogueroles M, Damms-Machado A, Sookthai D, Johnson T, et al. Prediagnostic plasma bile acid levels and colon cancer risk: a prospective study. J Natl Cancer Inst. 2020;112:516\u201324.","journal-title":"J Natl Cancer Inst"},{"key":"1017_CR25","doi-asserted-by":"publisher","first-page":"4629","DOI":"10.1002\/cam4.3986","volume":"10","author":"C Yu","year":"2021","unstructured":"Yu C, You M, Zhang P, Zhang S, Yin Y, Zhang X. A five-gene signature is a prognostic biomarker in pan-cancer and related with immunologically associated extracellular matrix. Cancer Med. 2021;10:4629\u201343.","journal-title":"Cancer Med"},{"key":"1017_CR26","doi-asserted-by":"publisher","first-page":"xii44","DOI":"10.1093\/annonc\/mdx237","volume":"28","author":"AR S\u00e1nchez-Paulete","year":"2017","unstructured":"S\u00e1nchez-Paulete AR, Teijeira A, Cueto FJ, Garasa S, P\u00e9rez-Gracia JL, S\u00e1nchez-Arr\u00e1ez A, et al. Antigen cross-presentation and T-cell cross-priming in cancer immunology and immunotherapy. Ann Oncol. 2017;28:xii44\u201355.","journal-title":"Ann Oncol"},{"key":"1017_CR27","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1111\/imr.12766","volume":"290","author":"BA Wilky","year":"2019","unstructured":"Wilky BA. Immune checkpoint inhibitors: the linchpins of modern immunotherapy. Immunol Rev. 2019;290:6\u201323.","journal-title":"Immunol Rev"},{"key":"1017_CR28","doi-asserted-by":"publisher","first-page":"e0197694","DOI":"10.1371\/journal.pone.0197694","volume":"13","author":"PO Ilyinskii","year":"2018","unstructured":"Ilyinskii PO, Kovalev GI, O'neil CP, Roy CJ, Michaud AM, Drefs NM, et al. Synthetic vaccine particles for durable cytolytic T lymphocyte responses and anti-tumor immunotherapy. PLoS One. 2018;13:e0197694.","journal-title":"PLoS One"},{"key":"1017_CR29","doi-asserted-by":"publisher","first-page":"3009","DOI":"10.2174\/0929867324666170804143706","volume":"26","author":"B Li","year":"2019","unstructured":"Li B, Chan HL, Chen P. Immune checkpoint inhibitors: basics and challenges. Curr Med Chem. 2019;26:3009\u201325.","journal-title":"Curr Med Chem"},{"key":"1017_CR30","doi-asserted-by":"publisher","first-page":"e1655362","DOI":"10.1080\/2162402X.2019.1655362","volume":"8","author":"E Billon","year":"2019","unstructured":"Billon E, Finetti P, Bertucci A, Niccoli P, Birnbaum D, Mamessier E, et al. PDL1 expression is associated with longer postoperative, survival in adrenocortical carcinoma. Oncoimmunology. 2019;8:e1655362.","journal-title":"Oncoimmunology"},{"key":"1017_CR31","doi-asserted-by":"publisher","first-page":"847","DOI":"10.1158\/1535-7163.MCT-14-0983","volume":"14","author":"SP Patel","year":"2015","unstructured":"Patel SP, Kurzrock R. PD-L1 expression as a predictive biomarker in cancer immunotherapy. Mol Cancer Ther. 2015;14:847\u201356.","journal-title":"Mol Cancer Ther"},{"key":"1017_CR32","doi-asserted-by":"publisher","first-page":"2598","DOI":"10.1158\/1535-7163.MCT-17-0386","volume":"16","author":"G Am","year":"2017","unstructured":"Am G, Kato S, Bazhenova L, Sp P, Gm F, Miller V, et al. Tumor mutational burden as an independent predictor of response to immunotherapy in diverse cancers. Mol Cancer Ther. 2017;16:2598\u2013608.","journal-title":"Mol Cancer Ther"},{"key":"1017_CR33","doi-asserted-by":"publisher","first-page":"470","DOI":"10.1634\/theoncologist.2019-0563","volume":"25","author":"X Yang","year":"2020","unstructured":"Yang X, Shi J, Chen X, Jiang Y, Zhao H. Efficacy of Cabozantinib and Nivolumab in treating hepatocellular carcinoma with RET amplification, high tumor mutational burden, and PD-L1 expression. Oncologist. 2020;25:470\u20134.","journal-title":"Oncologist"},{"key":"1017_CR34","doi-asserted-by":"publisher","first-page":"1069","DOI":"10.1158\/2159-8290.CD-18-0367","volume":"8","author":"SC Wei","year":"2018","unstructured":"Wei SC, Duffy CR, Allison JP. Fundamental mechanisms of immune checkpoint blockade therapy. Cancer Discov. 2018;8:1069\u201386.","journal-title":"Cancer Discov"},{"key":"1017_CR35","doi-asserted-by":"publisher","first-page":"e542","DOI":"10.1016\/S1470-2045(16)30406-5","volume":"17","author":"GT Gibney","year":"2016","unstructured":"Gibney GT, Weiner LM, Atkins MB. Predictive biomarkers for checkpoint inhibitor-based immunotherapy. Lancet Oncol. 2016;17:e542\u201351.","journal-title":"Lancet Oncol"},{"key":"1017_CR36","doi-asserted-by":"publisher","first-page":"3119","DOI":"10.1200\/JCO.2016.67.9761","volume":"34","author":"C Massard","year":"2016","unstructured":"Massard C, Gordon MS, Sharma S, Rafii S, Wainberg ZA, Luke J, et al. Safety and efficacy of Durvalumab (MEDI4736), an anti-programmed cell death Ligand-1 immune checkpoint inhibitor, in patients with advanced urothelial bladder cancer. J Clin Oncol. 2016;34:3119\u201325.","journal-title":"J Clin Oncol"},{"key":"1017_CR37","doi-asserted-by":"publisher","first-page":"541","DOI":"10.1038\/s41591-018-0014-x","volume":"24","author":"M Binnewies","year":"2018","unstructured":"Binnewies M, Roberts EW, Kersten K, Chan V, Fearon DF, Merad M, et al. Understanding the tumor immune microenvironment (TIME) for effective therapy. Nat Med. 2018;24:541\u201350.","journal-title":"Nat Med"},{"key":"1017_CR38","doi-asserted-by":"publisher","first-page":"8509","DOI":"10.1002\/jcp.27782","volume":"234","author":"B Farhood","year":"2019","unstructured":"Farhood B, Najafi M, Mortezaee K. CD8(+) cytotoxic T lymphocytes in cancer immunotherapy: a review. J Cell Physiol. 2019;234:8509\u201321.","journal-title":"J Cell Physiol"},{"key":"1017_CR39","doi-asserted-by":"publisher","first-page":"578","DOI":"10.1002\/gcc.22733","volume":"58","author":"A Stenzinger","year":"2019","unstructured":"Stenzinger A, Jd A, Maas J, Md S, Dm M, Mm W, et al. Tumor mutational burden standardization initiatives: recommendations for consistent tumor mutational burden assessment in clinical samples to guide immunotherapy treatment decisions. Gen Chromosomes Cancer. 2019;58:578\u201388.","journal-title":"Gen Chromosomes Cancer"},{"key":"1017_CR40","doi-asserted-by":"publisher","first-page":"1837","DOI":"10.1016\/S0140-6736(16)00587-0","volume":"387","author":"L Fehrenbacher","year":"2016","unstructured":"Fehrenbacher L, Spira A, Ballinger M, Kowanetz M, Vansteenkiste J, Mazieres J, et al. Atezolizumab versus docetaxel for patients with previously treated non-small-cell lung cancer (POPLAR): a multicentre, open-label, phase 2 randomised controlled trial. Lancet. 2016;387:1837\u201346.","journal-title":"Lancet"},{"key":"1017_CR41","doi-asserted-by":"publisher","first-page":"525","DOI":"10.1016\/j.annonc.2020.01.006","volume":"31","author":"M Chalabi","year":"2020","unstructured":"Chalabi M, Cardona A, Nagarkar DR, Dhawahir SA, Gandara DR, Rittmeyer A, et al. Efficacy of chemotherapy and atezolizumab in patients with non-small-cell lung cancer receiving antibiotics and proton pump inhibitors: pooled post hoc analyses of the OAK and POPLAR trials. Ann Oncol. 2020;31:525\u201331.","journal-title":"Ann Oncol"},{"key":"1017_CR42","doi-asserted-by":"publisher","first-page":"e000469","DOI":"10.1136\/jitc-2019-000469","volume":"8","author":"LS Landwehr","year":"2020","unstructured":"Landwehr LS, Altieri B, Schreiner J, Sbiera I, Weigand I, Kroiss M, et al. Interplay between glucocorticoids and tumor-infiltrating lymphocytes on the prognosis of adrenocortical carcinoma. J Immunother Cancer. 2020;8:e000469.","journal-title":"J Immunother Cancer"},{"key":"1017_CR43","doi-asserted-by":"publisher","first-page":"8276","DOI":"10.1158\/0008-5472.CAN-10-2014","volume":"70","author":"B Ragazzon","year":"2010","unstructured":"Ragazzon B, Lib\u00e9 R, Gaujoux S, Assi\u00e9 G, Fratticci A, Launay P, et al. Transcriptome analysis reveals that p53 and {beta}-catenin alterations occur in a group of aggressive adrenocortical cancers. Cancer Res. 2010;70:8276\u201381.","journal-title":"Cancer Res"},{"key":"1017_CR44","doi-asserted-by":"publisher","first-page":"2029","DOI":"10.2147\/OTT.S159979","volume":"11","author":"S Liu","year":"2018","unstructured":"Liu S, Ding G, Zhou Z, Feng C. \u03b2-Catenin-driven adrenocortical carcinoma is characterized with immune exclusion. OncoTargets Ther. 2018;11:2029\u201336.","journal-title":"OncoTargets Ther"},{"key":"1017_CR45","doi-asserted-by":"publisher","first-page":"695","DOI":"10.1093\/jnci\/djy157","volume":"111","author":"WL Hwang","year":"2019","unstructured":"Hwang WL, Wolfson RL, Niemierko A, Marcus KJ, Dubois SG, Haas-Kogan D. Clinical impact of tumor mutational burden in neuroblastoma. J Natl Cancer Inst. 2019;111:695\u20139.","journal-title":"J Natl Cancer Inst"},{"key":"1017_CR46","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1186\/s12885-020-6658-1","volume":"20","author":"L Wang","year":"2020","unstructured":"Wang L, Ge J, Lan Y, Shi Y, Luo Y, Tan Y, et al. Tumor mutational burden is associated with poor outcomes in diffuse glioma. BMC Cancer. 2020;20:213.","journal-title":"BMC Cancer"},{"key":"1017_CR47","doi-asserted-by":"publisher","first-page":"2995","DOI":"10.1200\/JCO.2018.78.1963","volume":"36","author":"S Devarakonda","year":"2018","unstructured":"Devarakonda S, Rotolo F, Tsao MS, Lanc I, Brambilla E, Masood A, et al. Tumor mutation burden as a biomarker in resected non-small-cell lung cancer. J Clin Oncol. 2018;36:2995\u20133006.","journal-title":"J Clin Oncol"},{"key":"1017_CR48","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1016\/j.ejca.2020.02.038","volume":"131","author":"JD Fumet","year":"2020","unstructured":"Fumet JD, Truntzer C, Yarchoan M, Ghiringhelli F. Tumour mutational burden as a biomarker for immunotherapy: current data and emerging concepts. Eur J Cancer. 2020;131:40\u201350.","journal-title":"Eur J Cancer"},{"key":"1017_CR49","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1038\/s41588-018-0312-8","volume":"51","author":"RM Samstein","year":"2019","unstructured":"Samstein RM, Lee CH, Shoushtari AN, Hellmann MD, Shen R, Janjigian YY, et al. Tumor mutational load predicts survival after immunotherapy across multiple cancer types. Nat Genet. 2019;51:202\u20136.","journal-title":"Nat Genet"},{"key":"1017_CR50","doi-asserted-by":"publisher","first-page":"e127901","DOI":"10.1172\/jci.insight.127901","volume":"4","author":"Q Jia","year":"2019","unstructured":"Jia Q, Wang J, He N, He J, Zhu B. Titin mutation associated with responsiveness to checkpoint blockades in solid tumors. JCI Insight. 2019;4:e127901.","journal-title":"JCI Insight"},{"key":"1017_CR51","doi-asserted-by":"publisher","first-page":"1691","DOI":"10.1001\/jamaoncol.2018.2805","volume":"4","author":"X Li","year":"2018","unstructured":"Li X, Pasche B, Zhang W, Chen K. Association of MUC16 mutation with tumor mutation load and outcomes in patients with gastric cancer. JAMA Oncol. 2018;4:1691\u20138.","journal-title":"JAMA Oncol"},{"key":"1017_CR52","doi-asserted-by":"publisher","first-page":"e2013201","DOI":"10.1001\/jamanetworkopen.2020.13201","volume":"3","author":"L Zhang","year":"2020","unstructured":"Zhang L, Han X, Shi Y. Association of MUC16 mutation with response to immune checkpoint inhibitors in solid tumors. JAMA Netw Open. 2020;3:e2013201.","journal-title":"JAMA Netw Open"},{"key":"1017_CR53","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1186\/1476-4598-13-129","volume":"13","author":"M Felder","year":"2014","unstructured":"Felder M, Kapur A, Gonzalez-Bosquet J, Horibata S, Heintz J, Albrecht R, et al. MUC16 (CA125): tumor biomarker to cancer therapy, a work in progress. Mol Cancer. 2014;13:129.","journal-title":"Mol Cancer"}],"container-title":["BMC Endocrine Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12902-022-01017-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12902-022-01017-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12902-022-01017-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,5,14]],"date-time":"2022-05-14T09:09:06Z","timestamp":1652519346000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcendocrdisord.biomedcentral.com\/articles\/10.1186\/s12902-022-01017-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,5,14]]},"references-count":53,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2022,12]]}},"alternative-id":["1017"],"URL":"https:\/\/doi.org\/10.1186\/s12902-022-01017-3","relation":{},"ISSN":["1472-6823"],"issn-type":[{"value":"1472-6823","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,5,14]]},"assertion":[{"value":"15 June 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 April 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 May 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Our study did not require an ethical board approval because it did not contain human or animal trials.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"130"}}